Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* CF as diagnosed by:~  1. Documented sweat chloride greater than or equal to 60 mEq/L by quantitative pilocarpine iontophoresis test; or~ 2. Two well-characterized genetic mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene; or~ 3. Abnormal nasal potential difference with accompanying symptoms characteristic of CF.~* PA present in expectorated sputum or throat swab culture at Screening.~* Participants must have received three or more courses of TIS within the previous 12 months.~* Participants on chronic azithromycin must have had no change in regimen in the previous 3 months and must have had a need for TIS and/or additional antipseudomonal therapy since initiation of azithromycin.~* Forced expiratory volume in 1 second (FEV1) between (and including) 25% and 75% predicted at Screening.~* Ability to perform reproducible pulmonary function tests.~* Arterial oxygen saturation (SaO2) greater than or equal to 90% on room air at Screening.~Exclusion Criteria:~* Current use of oral corticosteroids in doses exceeding the equivalent of 10 mg prednisone a day or 20 mg prednisone every other day.~* History of sputum or throat culture swab yielding Burkholderia cepacia in the past 2 years.~* History of daily continuous oxygen supplementation or requirement for more than 2 liters/minute at night.~* Administration of any investigational drug or device within 28 days of Screening (Visit 1) or within 6 half-lives of the investigational drug (whichever was longer).~* Known local or systemic hypersensitivity to monobactam antibiotics.~* Inability to tolerate inhalation of a short acting Beta-2 agonist.~* Changes in antimicrobial, bronchodilator, anti-inflammatory, or corticosteroid medications within 7 days before Screening or between Screening and the next visit.~* Changes in physiotherapy technique or schedule within 7 days before Screening or between Screening and the next visit.~* History of lung transplantation.~* A chest X-ray indicating abnormal findings at Screening or within the previous 90 days.~* Abnormal renal or hepatic function or serum chemistry at Screening (aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\] greater than 5 times the upper limit of normal range; Creatinine greater than 2 times the upper limit of normal range).~* Positive pregnancy test at Screening.~* Female of childbearing potential who was lactating or in the opinion of the investigator was not practicing acceptable birth control.~* Any serious or active medical or psychiatric illness, which in the opinion of the investigator would have interfered with participant treatment, assessment, or compliance with the protocol.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (pooled two times a day [BID]/three times a day [TID]) (Type: PLACEBO_COMPARATOR): None
- AZLI (pooled two times a day [BID]/three times a day [TID]) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete